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Abstract A significant proportion of P-glycoprotein (P-gp) and
caveolin was co-localized in caveolae isolated from resistant
(CHRC5) cells overexpressing P-gp and from drug-sensitive
Chinese hamster ovary cells (AuxB1). The proportion of P-gp
and caveolin associated with caveolar microdomains was higher
in CHRC5 cells grown in the presence of P-gp substrates
(cyclosporin A or colchicine) than in untreated CHRC5 cells. Co-
immunoprecipitation of P-gp and caveolin from CHRC5 lysates
suggests that there is a physical interaction between them.
Furthermore, co-localization of P-gp and caveolin was found in
caveolae from brain capillaries, indicating that this association
also takes place in vivo.
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1. Introduction
Multidrug resistance phenotype in cancer cells has been
associated with P-glycoprotein (P-gp) expression [1,2]. P-gp
is a member of the ABC (ATP binding cassette) superfamily
of transporters, which excludes from cells a wide variety of
anticancer drugs and hydrophobic molecules [3]. This capacity
of P-gp to interact with a large panoply of hydrophobic sub-
strates [2,4^6], either endogenous (hydrophobic peptides and
steroids) or exogenous (cyclosporin A (CsA), verapamil, cal-
modulin antagonists, etc.), suggests an important role for P-gp
in drug metabolism and disposal. Its importance as a phar-
macological target for drugs has far exceeded the role initially
found for it as an export protein in multidrug resistance [7^9].
Previous studies have also proposed that P-gp may be in-
volved in the intracellular processing of cholesterol and in
lipid transport across membranes [10^15].
In various MDR cells changes in membrane lipid composi-
tion have been reported (elevated levels of cholesterol, glyco-
sphingolipids and sphingolipids) [16]. High amounts of cho-
lesterol, sphingomyelin and glycosphingolipids are found in
invaginated microdomains of the plasma membrane called
caveolae [17,18]. These microdomains are present in a wide
variety of cell types and are dynamic structures involved in
transcytosis, potocytosis and signal transduction [19,20]. In
addition to their distinct lipid composition, caveolar domains
include signaling molecules such as tyrosine kinases [21], pro-
tein kinase C [22], growth factor receptors [23,24], glycerol-
phosphatidylinositol-linked receptors, and GTPases such as
Ras [25], Rap [26], RhoA [27] and subunits of heterotrimeric
G proteins [28,29]. Recent studies have also shown that a
portion of P-gp is localized in low density detergent-insoluble
membrane fractions derived from a human colon adenocarci-
noma cell line (HT-29-MDR) and from an MCF-7 cell line
stably transfected with P-gp [30].
Caveolin, a 22 kDa integral membrane protein, is a marker
of caveolae which binds cholesterol, interacts with other pro-
teins and may play an important structural role in the forma-
tion of caveolae [19,20,31,32]. In the present study, co-local-
ization of P-gp and caveolin was observed in sensitive cells
(AuxB1) and in resistant cells (CHRC5) overexpressing P-gp.
Experiments were performed to determine whether this co-
localization of P-gp is altered in resistant cells exposed to P-
gp substrates (colchicine and CsA). Co-immunoprecipitation
of both proteins was also carried out to evaluate whether P-gp
and caveolin could be physically associated. Furthermore, us-
ing brain capillaries where P-gp expression is very highly ex-
pressed [33], we examine the possibility that P-gp is also lo-
calized in caveolae-enriched microdomains in vivo.
2. Materials and methods
2.1. Chemicals
Sensitive (AuxB1) and resistant (CHRC5) cell lines were grown in
alpha-MEM from Gibco BRL (Burlington, Ont., Canada) and 10%
serum from HyClone Laboratories (Logan, UT, USA). Electrophore-
sis reagents were purchased from Bio-Rad (Mississauga, Ont.,
Canada). MAbs C219 and Ab-2, directed against P-gp, were from
ID Labs (London, Ont., Canada) and from NeoMarkers (Union
City, CA, USA), respectively. PAbs against caveolin and paxillin
were obtained from Transduction Laboratories (Lexington, KY,
USA). The pAb directed against caveolin-1 linked to agarose beads
and the pAb against focal adhesion kinase (FAK) were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-mouse and anti-
rabbit IgG horseradish peroxidase-linked whole antibody were pur-
chased from Jackson ImmunoResearch Laboratories (West Grove,
PA, USA) and enhanced chemiluminescence (ECL) reagents were
from Amersham Pharmacia Biotech (Baie d’Urfe¤e, Que., Canada).
All other reagents were from Sigma-Aldrich Canada (Oakville, Ont.,
Canada).
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2.2. Isolation of caveolae-enriched membrane domains
Low-density caveolae-enriched domains were isolated by a carbo-
nate-based fractionation method as described previously [25]. Brie£y,
con£uent CHRC5 or AuxB1 cells cultured in 100 mm dishes (contain-
ing about 107 cells) were scraped into 2 ml of 0.5 M sodium carbonate
(pH 11) and homogenized extensively using a Dounce homogenizer
(10 strokes), a Polytron tissue grinder (three 10 s bursts at medium
speed) and a sonicator (three 20 s bursts at 50% maximal power). The
resulting homogenate was brought to 45% sucrose by the addition of
2 ml of 90% sucrose in Mes-bu¡ered saline (MBS; 25 mM Mes, pH
6.5, 150 mM NaCl) and overlaid with two layers of 35% and 5%
sucrose in MBS containing 0.25 M carbonate (4 ml each). The gra-
dient was then centrifuged at 200 000Ug for 18 h using a Beckman
SW41Ti rotor. For the analysis of the resulting gradient, 1 ml frac-
tions were collected from the top to the bottom of the gradient. 10 or
20 Wl from each fraction was subjected to SDS-PAGE for the detec-
tion of P-gp or caveolin, respectively.
2.3. Detection of P-gp, caveolin, FAK and paxillin
P-gp, caveolin, FAK and paxillin were detected by Western blot
analysis. Proteins from CHRC5 or AuxB1 cells were resolved by so-
dium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Samples were resuspended in sample bu¡er and loaded on 7.5% acryl-
amide-bisacrylamide (29.2:0.8) gels for P-gp and FAK or 12.5% acryl-
amide-bisacrylamide gels for caveolin and paxillin. P-gp was detected
(without prior heating) using mAb C219 as described previously [33]
while caveolin was evaluated using a pAb [27]. Gels were subjected to
SDS-PAGE and electroblotted onto PVDF membranes using stand-
ard procedures. Blots were blocked overnight in Tris-bu¡ered saline
(TBS; 147 mM NaCl, 20 mM Tris^HCl, pH 7.5 and 0.3% Tween 20)
containing 5% non-fat dry milk, followed by a 1 h 30 min incubation
with the primary antibody. Blots were washed three times with TBS
containing 0.3% Tween 20 followed by a 1 h incubation with horse-
radish peroxidase-conjugated antibodies directed against mouse and
rabbit IgGs. Blots were again washed three times with TBS and 0.3%
Tween 20, and detection was performed with ECL reagents (Amer-
sham) according to the manufacturer’s instructions.
2.4. Immunoprecipitation procedures
Con£uent CHRC5 or AuxB1 cells cultured in 100 mm dishes were
washed with PBS (150 mM NaCl, 2.7 mM KCl, 1.3 mM KH2PO4, 8.1
mM Na2HPO4W7H2O, pH 7.4), lysed in ice-cold lysis bu¡er containing
1% Triton X-100, 0.5% Nonidet P-40, 60 mM N-octylglucoside, 1 mM
EDTA, 1 mM EGTA, 10 mM Tris^HCl (pH 7.4) and insoluble ma-
terial was removed by centrifugation at 10 000Ug for 10 min. The
lysate (100 Wg) was precleared by incubation for 1 h with Protein G-
Sepharose beads and incubated overnight with 1 Wg of monoclonal
anti-P-gp antibodies (C219 or Ab-2) or 1 Wg of anti-caveolin antibody
linked to agarose beads. The immune complexes were collected fol-
lowing a 2 h incubation with protein G-Sepharose beads and washed
extensively (three times) with the lysis bu¡er. The beads were resus-
pended in 20 Wl of two-fold concentrated Laemmli electrophoresis
bu¡er, separated by SDS-PAGE and electroblotted onto PVDF mem-
branes for the detection of caveolin or P-gp.
3. Results and discussion
3.1. Detection of P-gp and caveolin
In the present study, we ¢rst investigated the levels of P-gp
and caveolin in resistant (CHRC5) and sensitive (AuxB1) cells
(Fig. 1). P-gp levels detected by Western blots using mAb
C219 were much higher in CHRC5 cells (around 75-fold high-
er) than in AuxB1 cells. The levels of caveolin were similar in
both types of cells. This is in contrast to a previous study that
reported an up-regulation of caveolin-1 in multidrug-resistant
HT-29 human colon adenocarcinoma cells and in Taxol-re-
sistant A549 cells compared to the corresponding sensitive
cells [34]. As a control, L-actin was also evaluated in both
cell lines. Its level was identical in the cell lines, indicating
that equal amounts of proteins were loaded onto the Western
blots.
3.2. Co-sedimentation of P-gp with caveolar membrane proteins
Caveolae-enriched membrane microdomains were isolated
both from resistant (CHRC5) cells grown in the presence of
colchicine and from sensitive (AuxB1) cells (Fig. 2). Both cells
samples were fractionated by a carbonate-based fractionation
method, in the absence of detergent, for the isolation of cav-
eolae. Caveolin-1, a caveolae marker [19,20], as well as P-gp,
paxillin and FAK were detected by Western blots in fractions
Fig. 1. Immunodetection of P-gp and caveolin in CHRC5 and
AuxB1 cells. P-gp was detected in lysates from CHRC5 cells (2 Wg
of protein) or AuxB1 cells (20 Wg of protein). Caveolin and L-actin
were also detected in lysates (20 Wg of protein) from both cell lines
by Western blot as described under Section 2.
Fig. 2. Distribution of caveolin and P-gp following fractionation of CHRC5 and AuxB1 cells. CHRC5 cells, grown in the presence of colchicine,
and AuxB1 cells were subjected to subcellular fractionation after homogenization in bu¡er containing 0.25 M sodium carbonate, as described
previously under Section 2. Gradients were fractionated by collecting 1 ml fractions from the top and 10 Wl or 20 Wl of each fraction were
loaded onto acrylamide gels for the detection of caveolin, P-gp, FAK and paxillin. For AuxB1 fractions, longer ¢lm exposure was required for
the detection of P-gp compared to the time needed for the detection of P-gp in the CHRC5 fractions. One representative experiment is shown.
(n = 3)
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collected from the resulting sucrose gradient. In CHRC5 frac-
tions, the major proportions of caveolin and P-gp co-sedi-
mented at the low-density sucrose interface (fractions 4^6).
Paxillin and Fak, which are negative markers of caveolae
domains in endothelial cells, were only detected in fractions
9^12 [27]. The absence of paxillin and Fak in the low-density
sucrose fractions, which correspond to caveolae, indicates that
the co-localization of P-gp and caveolin is not caused by the
presence of other types of membrane domains. In fractions
from sensitive cells (AuxB1), caveolin was detected in the low-
density sucrose (fractions 4^6) and a considerable amount of
caveolin was also detected in the high-density sucrose inter-
face (fractions 9^12) of the gradient. A longer ¢lm exposure
was required for ECL-detection of P-gp in the fractions iso-
lated from AuxB1 cells than for those from CHRC5 cells. In
AuxB1 cells, P-gp was present in fractions 4^6 as well as in
fractions 9^12 suggesting that P-gp co-sedimented with cav-
eolin in both resistant and sensitive cells.
A previous study detected functional intracellular P-gp in
CHRC5 cytoplasmic vesicles [35]. The origin and nature of
these vesicles containing P-gp is unknown and they are not
associated with pinocytotic vesicles. Our results indicate that a
major proportion of P-gp in CHRC5 is co-localized with cav-
eolin, suggesting association with caveolar-like microdomains.
Up-regulation of caveolin in caveolar-like structures by 12
and ¢ve-fold was observed in resistant human colon adeno-
carcinoma cells (HT-29-MDR cells) and in adriamycin-resist-
ant MCF-7 human breast carcinoma transfected with P-gp,
compared to their corresponding sensitive parental cells
[16,30]. A portion of P-gp (40%) was reported to be present
in low-density detergent-insoluble membranes derived from
either of these cell lines, suggesting the presence of P-gp in
caveolar domains. In addition, caveolin was shown to be var-
iably expressed in di¡erent MDR-cell lines and was not ex-
pressed in the corresponding parental drug-sensitive cells
[30,34]. In contrast to these results, the levels of caveolin
(on a equal protein basis) were very similar in resistant
CHRC5 cells and in sensitive AuxB1 cells. Thus the endoge-
nous level of caveolin in AuxB1 cells is not up-regulated dur-
ing the acquisition of resistance by CHRC5 cells, suggesting
that augmentation of the levels of caveolin in these cells is not
required for the development of the MDR-phenotype. This is
in contrast to a previous study reporting that up-regulation of
caveolin-1 in Taxol-resistant A549 cells may play a role in the
development of Taxol resistance but occurs independently of
P-gp expression [34].
3.3. Modulation of the localization of P-gp in caveolae by drug
treatment
We further investigated the e¡ects of drugs such as colchi-
cine and CsA on P-gp localization in caveolar-like microdo-
mains (Fig. 3). Colchicine was used since CHRC5 cells were
selected for their resistance to this drug whereas CsA is known
as a reversing agent. CHRC5 cells were grown in the presence
or absence of the reversing agent CsA (10 WM) or colchicine
(4 Wg/ml). First, P-gp and caveolin were immunodetected in
CHRC5 cell lysates following CsA and colchicine treatments
(Fig. 3A). Neither CsA nor colchicine a¡ected P-gp or cav-
eolin expression in CHRC5 cells. Second, the same number of
cells for each treatment was fractionated by the carbonate
method for isolation of the caveolar-like microdomains (Fig.
3B). When CHRC5 cells were grown in the absence of drugs
(CsA or colchicine), two populations of P-gp and caveolin
were immunodetected. One population was associated with
fractions 4^6 and the other was detected in fractions 9^12.
The pro¢le of distribution of both proteins in these fractions
was modi¢ed when cells were grown in the presence of CsA or
colchicine. P-gp became more strongly detected in fractions 4^
6, suggesting a subcellular redistribution of the protein in
CHRC5 cells caused by both drugs. In sensitive cells
(AuxB1), the levels of P-gp and caveolin as well as their dis-
tribution in sucrose fractions were una¡ected by CsA (data
not shown). Caveolin was also detected in fractions 4^6 rather
than in fractions 9^12 when resistant cells were grown in the
presence of both drugs, suggesting a subcellular redistribution
of caveolin.
P-gp and caveolin were also evaluated using equal amounts
of proteins from caveolar fractions (4^6) and non-caveolar
fractions (9^12) (Fig. 4A). In the absence of drugs, the ratio
of the levels for both P-gp and caveolin in the caveolar and
non-caveolar fractions clearly indicate that on an equal pro-
tein basis P-gp and caveolin are equally distributed in these
fractions (Fig. 4B). This ratio for both proteins (P-gp or cav-
eolin) increased to 10^12 and 20^22 when CHRC5 cells were
Fig. 3. E¡ect of drug treatments on P-gp localization in caveolae-
enriched domains. CHRC5 were grown to con£uence in the absence
of any drug (Ctl) or in the presence of cyclosporin A (CsA, 10 WM)
or colchicine (Col, 4 Wg/ml). A: P-gp and caveolin were detected in
samples from lysed CHRC5 cells grown without drugs (Ctl) or in
the presence of CsA (CsA) or colchicine (Col) by Western blot anal-
ysis. For P-gp detection 2 Wg of protein were loaded onto the gel
whereas for caveolin detection 10 Wg of protein were used. B: Frac-
tionation of these cells was carried out using the carbonate-based
procedure. Distributions of P-gp and caveolin in fractions collected
from the gradients was evaluated by Western blot analysis as de-
scribed under Section 2. One representative experiment is shown.
(n = 3)
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grown in the presence of colchicine or CsA, respectively, sug-
gesting a strong enrichment of both proteins in the caveolar
fractions. These results indicate that drug treatments can
modify the subcellular localization of P-gp and caveolin and
that CsA or colchicine may promote an increase in the for-
mation of caveolar-like microdomains. It is unclear whether
this phenomenon is related to the interaction of both drugs
with P-gp or to other cellular events. For example, since col-
chicine is known to interfere with the formation of microtu-
bules, the presence of this drug might interfere with mem-
brane vesicle tra⁄cking and lead to a redistribution of P-gp
and caveolin. In the case of CsA, this reversing agent may
also a¡ect intracellular vesicle tra⁄cking since it was previ-
ously shown, in some human cancer cells, to interfere with the
metabolism of sphingolipid, one of the major constituents of
caveolae [36,37].
Previous studies have also described the accumulation of
drugs such as doxorubicin or daunorubicin into cytoplasmic
structures and intracellular vesicles in MDR-resistant cells
and that P-gp and the multidrug-associated protein (Mrp)
may be associated with these vesicles and contribute to the
sequestration of the drugs [35,38,39]. Our results suggest that
this previous cytoplasmic localization of P-gp and drugs in
intracellular vesicles may be associated with caveolae-like mi-
crodomains. Further studies are required to characterize the
presence of P-gp in caveolar-like domains in order to deter-
mine whether an intracellular pool of P-gp may a¡ect the
e⁄cacy of anti-cancer drugs or reversing agents.
3.4. Coimmunoprecipitation of caveolin and P-gp
To further investigate the association of P-gp with caveolae-
enriched membrane domains, immunoprecipitation using spe-
ci¢c mAbs against P-gp were performed (Fig. 4). P-gp was
immunoprecipitated with both mAbs C219 and Ab-2, which
recognize two di¡erent P-gp epitopes [40,41], and Western
blots of immunoprecipitates were carried out using a pAb
directed against caveolin (Fig. 5A). Controls with non-speci¢c
mouse IgGs and with protein G-Sepharose beads incubated
with or without cell lysates were also performed. In CHRC5
lysates, caveolin was detected at 23 kDa. When P-gp from
these cell lysates was immunoprecipitated by both C219 and
Ab-2 mAbs, caveolin could be immunodetected in the immune
complexes but not immunodetected when CHRC5 lysate was
incubated with non-speci¢c mouse IgGs. Furthermore, caveo-
lin was completely absent when CHRC5 cell lysates were omit-
ted during the immunoprecipitation procedures, clearly indi-
cating that the band corresponding to caveolin is not related
to the presence of the light antibody chains of C219 or Ab-2
detected at 23^25 kDa. In addition, P-gp was detected when
caveolin in CHRC5 lysates was immunoprecipitated using an
anti-caveolin antibody linked to agarose beads. Both of these
co-immunoprecipitation experiments indicate that there is a
physical interaction between P-gp and caveolin in resistant
Fig. 5. Co-immunoprecipitation of caveolin with P-gp in CHRC5
cells. A: P-gp was immunoprecipitated (IP) from CHRC5 cell ly-
sates, followed by immunodetection (ID) of caveolin, as follows.
Lysed CHRC5 cells (100 Wg) were precleared with protein G-Sephar-
ose beads. Overnight incubations with (+) or without (3) cell ly-
sates were performed in the presence of 1 Wg of non-speci¢c mouse
IgGs or 1 Wg of mAbs C219 or Ab-2. The immune complexes were
collected by the addition of Protein G-Sepharose beads and ana-
lyzed by SDS-PAGE using 12.5% polyacrylamide gels; caveolin was
immunodetected. B: Caveolin in CHRC5 lysates (100 Wg) was im-
munoprecipitated using an anti-caveolin antibody linked to agarose
beads, as follows. Lysed CHRC5 cells (100 Wg) were precleared with
protein G-Sepharose beads. The anti-caveolin antibody (2 Wg) linked
to agarose beads was incubated overnight in the absence (3) or in
the presence (+) of CHRC5 lysates. The immune complexes were
collected and analyzed by SDS-PAGE using 6.5% polyacrylamide
gels and P-gp was immunodetected with mAb C219. C: CHRC5
cells grown in the absence of drugs (Ctl) or in the presence of
CsA (10 WM) or colchicine (4 Wg/ml) were lysed and P-gp was im-
munoprecipitated (100 Wg) with mAb C219 as described under Sec-
tion 2. Caveolin was immunodetected using 12.5% polyacrylamide
gels. 10 Wg of lysed CHRC5 cells were used as a positive control.
Fig. 4. Detection of P-gp and caveolin in caveolar and non-caveolar
fractions. A: Fractions 4^6 (caveolar fractions) and 9^12 (non-cav-
eolar fractions) were pooled, diluted in Tris^HCl 10 mM, pH 7.5,
and centrifuged at 100 000Ug for 1 h 30 min. Equal amounts of
proteins (2 Wg) or 10 Wg of caveolar and non-caveolar fractions
were used to detect P-gp and caveolin, respectively. B: The bands
corresponding to both proteins were analyzed by laser densitometry.
The results were plotted as the ratios between relative band densities
of P-gp (open bars) and caveolin (closed bars) in caveolar fractions
and in non-caveolar fractions. One representative experiment is
shown. (n = 3)
FEBS 23235 21-1-00
M. Demeule et al./FEBS Letters 466 (2000) 219^224222
CHRC5 cells. Proteins that have been shown to interact with
caveolin have a consensus caveolin-binding motif
(xXXXXxXXx XXx, where x is an aromatic residue and
X is any amino acid) [42]. We found that this caveolin-binding
motif is present in P-gp between amino acid residues 36 and
44 (FTMFRYAGW). This raises the possibility that caveolin
interacts with the cytosolic N-terminal region of P-gp.
Since colchicine and CsA modulated the distribution of P-
gp and caveolin in CHRC5 cells, the association of caveolin
with P-gp was also evaluated in cells grown in the presence of
each drug (Fig. 5B). The levels of caveolin coimmunoprecipi-
tated with P-gp by mAb C219 were similar, indicating that the
physical interaction of P-gp and caveolin was una¡ected when
CHRC5 cells were exposed to colchicine or CsA. These results
suggest that the redistribution of both P-gp and caveolin in
CHRC5 cells by both drugs was not caused by a modulation
in the number of caveolin molecules bound to P-gp.
3.5. Co-localization of caveolin and P-gp in brain capillaries
To establish whether P-gp could be associated with caveolar
microdomains in vivo, the distribution of P-gp and caveolin
following fractionation of brain capillaries was determined
(Fig. 6). Brain capillaries were used since this tissue has one
of the highest levels of P-gp expression in vivo [33]. P-gp and
caveolin levels were determined in isolated brain capillaries
(10 Wg of protein) and in CHRC5 cells (2 Wg of protein)
(Fig. 6A). P-gp levels were approximately six-fold lower
than in CHRC5 cells whereas caveolin levels were eight-fold
higher in brain capillaries than in CHRC5 cells. As shown in
Fig. 6B, a fraction of P-gp co-localized with caveolin follow-
ing fractionation of isolated brain capillaries, suggesting that a
population of P-gp molecules in this tissue is associated with
these microdomains. Since P-gp levels were low in brain capil-
laries, immunoprecipitation experiments using brain capilla-
ries were performed with 500 Wg of protein instead of the
100 Wg of protein previously used for CHRC5 cells. When
P-gp from brain capillaries was immunoprecipitated with
mAbs C219 or Ab-2, caveolin was co-immunoprecipitated
(Fig. 6C). These results indicate that co-localization of P-gp
and caveolin as well as their physical association is not re-
stricted to cells selected in vitro for their resistance.
Further studies are needed to establish the exact implication
of the physical interaction between P-gp and caveolin. The
interaction of a number of proteins such as Ras, Src, protein
kinase C and the epidermal growth factor receptor with the
speci¢c sca¡olding domain of caveolin caused a strong inhib-
ition of their enzymatic activities suggesting that the interac-
tion of caveolin with P-gp may also negatively control its
activity [19]. Our results suggest that caveolae-like structures
containing P-gp may also be involved in the intracellular ac-
cumulation of anticancer drugs previously reported [35]. The
identi¢cation of the physical interaction of P-gp with caveolin
in caveolae-enriched membrane domains may provide new
insights in the understanding of the role and the regulation
of P-gp in caveolae-like domains. Furthermore, we have
shown that the association of P-gp with caveolae and the
physical interaction between P-gp and caveolin also takes
place in brain capillaries.
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